What is the Fiscal Year for Veradermics?
Date: November 13, 2026
Veradermics's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
New Haven, CT
Industry
Pharmaceutical Manufacturing
Stock Symbol
MANE
Website
www.veradermics.comDescription
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing new treatments for pattern hair loss (androgenetic alopecia). Pattern hair loss is a chronic condition affecting an estimated 50 million men and 30 million women in the U.S., with no new FDA-approved prescription medicines in nearly 30 years. Our mission is to set a new standard in pattern hair loss by developing treatments rooted in real evidence. Our lead investigational product, VDPHL01, is an oral, non-hormonal drug in Phase 3 development for pattern hair loss. If approved, VDPHL01 would be the only FDA-approved oral, non-hormonal treatment for pattern hair loss in both men and women. Beyond pattern hair loss, we aim to develop a focused portfolio of product candidates for high-prevalence aesthetic dermatology conditions, with the potential to selectively pursue medical dermatology opportunities.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Veradermics and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.